Clinical stage cannabinoid company Botanix Pharmaceuticals (ASX:BOT) has announced that Dr Mark Blaskovich presented antimicrobial data from studies recently conducted with its product candidate BTX 1801 at the American Society for Microbiology (ASM) Microbe 2019 Conference.
Dr Blaskovich’s presentation was titled ‘Cannabidiol is a Remarkably Active Gram-Positive Antibiotic’.
According to the presentation, cannabidiol is a broad-spectrum gram-positive antibiotic that is effective against a range of problematic human and animal bacteria.
Dr Blaskovich said the data showed it is effective against clinical isolates of staphylococcus aureus and methicillin resistance staphylococcus aureus (MRSA) and that bacteria do not form resistance to cannabidiol. In addition, cannabidiol kills bacteria very quickly and disrupts biofilms that bacteria use to protect themselves.
The studies were conducted at The University of Queensland’s Institute for Molecular Bioscience’s Centre for Superbug Solutions and supported by Innovation Connections, an Australian federal government grant.